Daily Newsletter

19 September 2023

Daily Newsletter

19 September 2023

Dassault launches digital twin ‘Emma’

The ‘Emma’ twin will document its participation in device and drug trials on social media.

Phalguni Deswal September 18 2023

Dassault Systèmes has launched an ‘Emma’ avatar for its digital twin technology to raise awareness regarding health research.

A digital twin of a human is a virtual model that is designed to accurately reflect the characteristics of the physical being. The ‘Emma Twin’ was developed using anonymous health data with the express purpose of conducting an infinite number of tests to glean more insight into various diseases and therapies.

‘Emma’ has documented her participation in ongoing research trials and medical innovations through LinkedIn. The page provides an overview of the research being conducted and a link to the project.

The highlighted project to be linked includes ‘Emma’s’ reaction to different simulation procedures in the Living Heart project, testing of CorNeat Vision corneal transplants, and Living Brain studies for epilepsy and Alzheimer’s disease.

The digital twin will also run simulations on wearable devices, including IASO drug administration and monitoring devices, Dynocardia’s blood pressure monitoring solution, FEops’ cardiac monitoring, customised facial implants by LUCID Implants, and the VORTHEx radiotherapy simulation experience.

GlobalData forecasts that the metaverse, including digital twin technology, could be worth $627bn in 2030. To that end, Accenture announced an investment into Virtonomy, to advance digital twin technology in the field of medical devices.

Dassault’s VP Victoire de Margerie stated that the digital twin technology can be used to “optimise surgical procedures and provide patients with a greater understanding of treatment options”. Adding that raising awareness through virtual worlds can improve real-life patient outcomes.

Multiple Myeloma (MM) pipeline dominated by CAR-T cells

The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close